The FGFR1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblast line. This product provides a loss-of-function model for the human FGFR1 gene, encoding fibroblast growth factor receptor 1, in a well-characterized hematopoietic suspension cell background. The polyclonal composition reflects a pooled knockout approach, suitable for population-level studies.
Raji cells are an EBV-positive B lymphoblast line established from a Burkitt lymphoma patient. They grow in suspension and exhibit B lymphocyte features including antigen presentation and immunoglobulin production, making them a standard model for B-cell malignancy and lymphocyte signaling research.
FGFR1 is a receptor tyrosine kinase that transduces signals from fibroblast growth factors (FGFs) including FGF1, FGF2, FGF4, FGF8, and FGF23, with heparan sulfate proteoglycans as obligate coreceptors. Ligand engagement induces receptor dimerization and autophosphorylation, creating docking sites for adaptor proteins FRS2, GRB2, SOS1, GAB1, and SHC1. These interactions initiate downstream cascades: the RAS-RAF-MEK-ERK pathway leading to phosphorylation of MAPK1/3, the PI3K-AKT pathway activating AKT1, and the PLC?? pathway with PLCG1 generating second messengers. These signals converge on transcription factors such as FOS, JUN, and STAT1, regulating gene expression programs that control cell proliferation, differentiation, migration, and survival. In the knockout model, disruption of FGFR1 abolishes these ligand-dependent signaling events, providing a defined loss-of-function background for mechanistic studies.
Within the Raji B lymphoblast context, FGFR1 is implicated in the proliferation and survival pathways that sustain malignant B cells. Aberrant FGF signaling has been documented in B-cell lymphomas, and this knockout model allows researchers to uncouple FGFR1-specific contributions from other regulatory inputs, such as B-cell receptor signaling and EBV latent gene expression. By eliminating FGFR1, the polyclonal cells offer a versatile platform to examine how this receptor modulates lymphoblast growth, apoptotic thresholds, and chemotactic responses.
Applications encompass target validation for FGFR1-directed therapeutics in B-lymphoma, dissection of FGF-dependent signal transduction, and functional genomics screens. Compatible experimental readouts include western blotting for FGFR1 and downstream phospho-proteins, RT-qPCR for transcriptional targets, flow cytometry for cell cycle and surface markers, proliferation and apoptosis assays, and migration assays. Additional approaches such as phospho-signaling multiplex analysis and inhibitor synergy studies are well suited to this polyclonal knockout system. For detailed product information and technical support, please contact Ascent Research.
